1800 El Camino Real
Suite D
Menlo Park, CA 94027
United States
650 331 9090
https://www.an2therapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 41
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Joseph S. Zakrzewski | Co-founder & Chairman of the Board | 76.5k | N/A | 1962 |
Mr. Eric E. Easom | Co-founder, CEO, President & Director | 920k | N/A | 1968 |
Ms. Lucy O. Day CPA | CFO, Principal Financial Officer & Principal Accounting Officer | 636.4k | N/A | 1959 |
Dr. Paul Eckburg M.D. | Chief Medical Officer | 688.2k | N/A | 1970 |
Dr. George Harrison Talbot FACP, M.D. | Co-Founder & Senior Clinical Advisor | N/A | N/A | 1948 |
Dr. Michael R. K. Alley Ph.D. | Co-Founder & Head of Biology | N/A | N/A | N/A |
Mr. Joshua Eizen J.D. | Chief Legal Officer & Secretary | 439.12k | N/A | 1978 |
Dr. Sanjay Chanda Ph.D. | Chief Development Officer | N/A | N/A | 1965 |
Mr. Kevin Krause B.S., M.B.A. | Chief Strategy Officer | N/A | N/A | 1975 |
Ms. Jennifer Huber | Senior Vice President of Regulatory Affairs & Quality | N/A | N/A | N/A |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.